PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
12.48%
Revenue growth under 50% of XRF.AX's 63.33%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
18.99%
Gross profit growth under 50% of XRF.AX's 82.03%. Michael Burry would be concerned about a severe competitive disadvantage.
70.35%
EBIT growth below 50% of XRF.AX's 488.26%. Michael Burry would suspect deeper competitive or cost structure issues.
70.35%
Operating income growth under 50% of XRF.AX's 488.26%. Michael Burry would be concerned about deeper cost or sales issues.
107.71%
Net income growth under 50% of XRF.AX's 769.99%. Michael Burry would suspect the firm is falling well behind a key competitor.
100.00%
EPS growth under 50% of XRF.AX's 700.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
100.00%
Diluted EPS growth under 50% of XRF.AX's 700.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
82.12%
Share count expansion well above XRF.AX's 13.12%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
82.12%
Diluted share count expanding well above XRF.AX's 13.12%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-274.48%
Negative OCF growth while XRF.AX is at 235.28%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-14.34%
Negative FCF growth while XRF.AX is at 999.46%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-96.30%
Negative 10Y revenue/share CAGR while XRF.AX stands at 28.54%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-57.39%
Negative 5Y CAGR while XRF.AX stands at 28.54%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-55.96%
Negative 3Y CAGR while XRF.AX stands at 26.57%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-103.53%
Negative 10Y OCF/share CAGR while XRF.AX stands at 3932.68%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
83.39%
Below 50% of XRF.AX's 3932.68%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-123.37%
Negative 3Y OCF/share CAGR while XRF.AX stands at 566.23%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
103.52%
Below 50% of XRF.AX's 780.74%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
126.47%
3Y net income/share CAGR 75-90% of XRF.AX's 160.35%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-94.74%
Our R&D shrinks while XRF.AX invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
580.87%
We expand SG&A while XRF.AX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.